Shares of Threshold Pharmaceuticals (NASDAQ:THLD) jumped up 15% today, bizarrely upon news that its competitor Celgene (NASDAQ:CELG) announced a set of successful phase 3 results. In this video, Motley Fool health-care analyst David Williamson tells investors what was behind this counterintuitive pop, and why it could be an excellent indicator for some of Threshold's own trials.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.